Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who ...
Steps taken to curb hepatitis B spread in Serian, Sarawak assembly told
KUCHING: The Serian area Health office in Sarawak is taking measures to curb hepatitis B in the division, says state Deputy ...
PharmiWeb4d
Global Hepatitis B Diagnostic Tests Market Poised for Significant Growth, Projected to Reach USD 1,744.26 Million by 2033
The global hepatitis B diagnostic tests market is on the cusp of substantial expansion, driven by a combination of increasing disease incidence, heightened global awareness campaigns, and rapid ...
manilatimes4d
Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Indaptus' Decoy product candidates have also produced meaningful single agent activity against chronic hepatitis B virus (HBV) and chronic human ... of the combination of BeiGene's anti-PD-1 antibody, ...
How evidence-based Ayurvedic research can help dispel myths surrounding cancer
On National Cancer Awareness Day, Dr Ravishankar Polisetty highlights the need to integrate Ayurvedic practices into modern medicine ...
Sudbury Star8d
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD – The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase ...
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...
Business Insider10d
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
Viral Reactivation: Hepatitis B virus (HBV) reactivation ... Fifty-six percent (161/285) of patients received intravenous immunoglobulin (IVIG) post CARVYKTI ® for either an adverse reaction or ...
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...
Medscape16d
Hepatitis B Vaccine Effectiveness in the Face of Global HBV Genotype Diversity
[25] In this study, specimens from all blood donations collected in 2008 were screened for HBsAg, anti-HBc (HBV core antibody) and HBV DNA. Nine HBsAg-seronegative individuals were found to have ...
Medscape18d
Diagnosis of Hepatitis B Virus Infection Through Serological and Virological Markers
ALT: Alanine aminotransferase; Anti-HBc: Hepatitis B core antibody; Anti-HBe: Hepatitis B e antibody; Anti-HBs: Hepatitis B surface antibody; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B ...
Future Market Insights21d
Global Chronic Hepatitis B Virus Testing Market Expected to Reach USD 1,790 Million by 2033 at a 6.9% CAGR
including the hepatitis B surface antigen (HBsAg), the hepatitis B core antibody (anti-HBc), the hepatitis B e antigen (HBeAg), and the hepatitis B surface antibody (anti-HBs). These markers help to ...